Novartis AG (FRA:NOTA) Cyclically Adjusted Book per Share: €26.93 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NOTA Novartis AG FRA:NOTA
81 GF Score
Price €134.00
GF Value €111.90
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis AG Cyclically Adjusted Book per Share?

Novartis AG FRA:NOTA 81 Cyclically Adjusted Book per Share is €26.93 as of Mar. 2026. GuruFocus rates FRA:NOTA with a GF Score™ of 81/100 and a GF Value™ of €111.90 (Modestly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Novartis AG's adjusted book value per share for the three months ended in Mar. 2026 was €17.459. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €26.93 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Novartis AG's average Cyclically Adjusted Book Growth Rate was -5.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -3.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -0.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Novartis AG was 4.60% per year. The lowest was -3.20% per year. And the median was 2.70% per year.

As of today (2026-07-14), Novartis AG's current stock price is €134.00. Novartis AG's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €26.93. Novartis AG's Cyclically Adjusted PB Ratio of today is 4.98.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novartis AG was 5.11. The lowest was 2.23. And the median was 2.84.


Novartis AG  (FRA:NOTA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Novartis AG's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=134.00/26.93
=4.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novartis AG was 5.11. The lowest was 2.23. And the median was 2.84.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Novartis AG Cyclically Adjusted Book per Share Related Terms


Novartis AG Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Novartis AG's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Cyclically Adjusted Book per Share Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.36 28.25 29.04 28.12 27.25

Novartis AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.80 27.70 28.09 27.25 26.93

FRA:NOTA vs LLY, JNJ, ABBV: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PB Ratio falls into.


FRA:NOTA
81GF Score
Novartis AG FRA:NOTA
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis AG Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novartis AG's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=17.459/108.0600*108.0600
=17.459

Current CPI (Mar. 2026) = 108.0600.

Novartis AG Quarterly Data

Book Value per Share CPI Adj_Book
201606 27.081 100.088 29.238
201609 28.125 99.604 30.513
201612 29.882 99.380 32.492
201703 26.713 100.040 28.855
201706 26.560 100.285 28.619
201709 26.179 100.254 28.217
201712 27.043 100.213 29.161
201803 24.738 100.836 26.510
201806 28.320 101.435 30.170
201809 28.915 101.246 30.861
201812 29.899 100.906 32.019
201903 17.994 101.571 19.144
201906 19.859 102.044 21.030
201909 21.060 101.396 22.444
201912 22.043 101.063 23.569
202003 20.128 101.048 21.525
202006 20.876 100.743 22.392
202009 20.337 100.585 21.848
202012 20.615 100.241 22.223
202103 18.903 100.800 20.265
202106 20.054 101.352 21.381
202109 21.571 101.533 22.958
202112 26.790 101.776 28.444
202203 25.255 103.205 26.443
202206 27.271 104.783 28.124
202209 28.558 104.835 29.437
202212 26.429 104.666 27.286
202303 23.187 106.245 23.583
202306 23.138 106.576 23.460
202309 17.397 106.570 17.640
202312 20.936 106.461 21.250
202403 17.889 107.355 18.006
202406 19.150 107.991 19.162
202409 19.521 107.468 19.629
202412 21.297 107.128 21.482
202503 18.115 107.722 18.172
202506 18.804 108.075 18.801
202509 19.684 107.710 19.748
202512 20.646 107.200 20.812
202603 17.459 108.060 17.459

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €26.93 mean?
Novartis AG (FRA:NOTA) has a Cyclically Adjusted Book per Share of €26.93 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novartis AG and its competitors.
Is Novartis AG's Cyclically Adjusted Book per Share too high?
Novartis AG's current Cyclically Adjusted Book per Share is €26.93. Overall, Novartis AG has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Cyclically Adjusted Book per Share compare to LLY and JNJ?
Novartis AG's Cyclically Adjusted Book per Share of €26.93 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novartis AG and its competitors. Novartis AG's current Cyclically Adjusted Book per Share is €26.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (FRA:NOTA) is currently considered Modestly Overvalued. The stock's GF Value™ is €111.90, compared to a current price of €134.00 — trading 19.7% above its estimated fair value. The current Cyclically Adjusted Book per Share is €26.93. Novartis AG's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Novartis AG (FRA:NOTA), the current Cyclically Adjusted Book per Share is €26.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (FRA:NOTA) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of €134.00 is trading 19.7% above its estimated GF Value™ of €111.90. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for FRA:NOTA:

  • Cyclically Adjusted Book per Share: €26.93
  • GF Value™: €111.90 vs. price of €134.00 (19.7% above fair value)
  • GF Score™: 81/100 with 7 warning signs

No single metric tells the full story. See the FRA:NOTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
81GF Score

Get the complete analysis for FRA:NOTA

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€134.00
Price
€111.90
GF Value